drugset
drugset / Trial / NCT04910022

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

NCT04910022 ↗

Phase 1/2 Active not recruiting 150 enrolled Nerviano Medical Sciences
NaSequentialOpen-labelTreatment

Summary

Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse.

Timeline

Start
2021-12-01
Primary completion
2027-05-30
Completion
2027-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject NMS-03305293 Unknown — Oral
Subject Temozolomide Small molecule — Oral

Indications

glioblastoma